<DOC>
	<DOCNO>NCT02769065</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , pharmacokinetic ( PK ) TAK-071 administer single rise dose ( SRD ) multiple rise dose ( MRD ) orally healthy participant participant mild cognitive impairment ( MCI ) mild Alzheimer disease ( AD ) .</brief_summary>
	<brief_title>Study TAK-071 Healthy Participants Participants With Mild Cognitive Impairment/Mild Alzheimer Disease Relative Bioavailability ( BA ) Food Effect TAK-071 Healthy Participants</brief_title>
	<detailed_description>TAK-071 test find safe well-tolerated dose healthy participant ( non-Japanese Japanese ) participant MCI mild AD ( non-Japanese ) . The study enroll approximately 174 participant . The study consist 4 part : Single-rising dose ( SRD ) part ( Cohorts 1-6 , 18-21 ) , multiple-rising dose ( MRD ) part ( Cohorts 7-15 ) , Cohort 16 2-way crossover design , Cohort 17 relative bioavailability food effect 3 period crossover design . Cohorts 1-12 18-19 , 8 randomized participant , 6 receive TAK-071 , 2 receive match placebo . Cohorts 20-21 12 randomized participant 3 receive TAK-071 placebo+donepezil placebo , 3 receive TAK-071 placebo+donepezil , 6 receive TAK-071+donepezil.Cohorts 13-15 , 6 randomized participant , 5 receive TAK-071 , 1 receive match placebo . Selected cohort ( Cohorts 10 12 ) pretreated 3 week daily oral dos donepezil ( 5 mg QD ) , follow continued daily oral donepezil dose TAK-071 treatment period . The planned initial dose TAK-071 Cohort 1 1 mg subsequent dose level determine emerge safety , tolerability , PK data preceding cohort . Participants cohort randomize receive treatment TAK-071 matching placebo use drug-in-capsule ( DIC ) morning follow minimum fast 8 hour . In Cohort 16 , participant assign 1 2 possible treatment sequence ( AB BA ) , Treatment A TAK-071 Treatment B match placebo . In Cohort 17 , 12 participant assign 1 3 treatment sequence ( ABC , BCA , CAB ) treatment A Fasted State Capsule Formulation , Treatment B Fasted State Tablet Formulation , Treatment C Fed State Tablet Formulation ( 10 mg tablet formulation ) . In Cohort 20-21 , participant administer single dose TAK-071 placebo Day 1 , single dose donepezil placebo approximately 24 hour later Day 2 .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>1 . Man woman weigh least 50 kg body mass index ( BMI ) 18.0 30.0 kg/m^2 , inclusive , Screening . 2 . For Cohorts 13 15 : Firstgeneration Japanese , define born Japan Japanese parent Japanese grandparent live 10 year outside Japan , significant change lifestyle , include diet , live outside Japan . 3 . Cohort 16 : Participants document previous diagnosis mild cognitive impairment ( MCI ) mild Alzheimer disease ( AD ) , Mini Mental State Examination score 20 30 , inclusive , biomarker data contradict diagnosis . Retrospectively , participant meet diagnosis probable AD base National Institute Neurological Disorders Stroke Alzheimer 's Disease Related Disorders Association criterion MCI diagnosis base criterion subjective cognitive complaint , evidence impairment 1 cognitive domain , preservation function , absence dementia . Participants must receive ongoing donepezil therapy ( 10 mg ) minimum 30 day . 1 . Has clinically significant ( Cohorts 1 15 17 21 ) uncontrolled ( Cohort 16 ) neurologic , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal ( GI ) , urologic , immunologic , endocrine , psychiatric disease abnormality ( disease study ) , may impact ability participant participate potentially confound study result . 2 . Has history type 1 diabetes ( Cohorts 1 21 ) type 2 diabetes ( Cohorts 1 15 , 17 21 ) hemoglobin A1c &gt; 6.5 % Screening . Note : participant control ( hemoglobin A1c &lt; 7.0 % Screening ) type 2 diabetes Cohort 16 may participate study . 3 . Has risk suicide suicidal ideation intent plan accord investigator 's clinical judgment ( affirmative answer question 4 5 ideation section ColumbiaSuicide Severity Rating Scale ) make suicide attempt previous 6 month . 4 . Cohort 16 : Any significant neurologic disease ( suspected incipient mild AD ) , Parkinson disease , stroke , transient ischemic attack , multiinfarct dementia , Huntington disease , head trauma clinically significant cognitive sequela , chronic central nervous system infection . 5 . Has current recent ( within 6 month ) GI disease would expect influence absorption drug ( ie , history malabsorption , surgical intervention know impact absorption [ eg , bariatric surgery bowel resection ] , esophageal reflux , peptic ulcer disease , erosive esophagitis , frequent [ per week ] occurrence heartburn ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>